HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

alunacedase alfa

Also Known As:

18-740-angiotensin-converting enzyme 2 (recombinant human apn01), dimer; APN-01; GSK-2586881; GSK2586881; recombinant soluble human angiotensin converting enzyme 2

Networked: 4 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1
- Enzymes: 152586
  - Hydrolases: 2166
    - Peptide Hydrolases: 23957
      - Exopeptidases: 68
        Carboxypeptidases: 268
        Angiotensin-Converting Enzyme 2: 2143
        alunacedase alfa: 4
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Recombinant Proteins: 2754
    - alunacedase alfa: 4

Experts

1.	Lazaar, Aili L: 2 articles (01/2022 - 01/2017)
2.	Powley, William M: 2 articles (01/2022 - 01/2017)
3.	Bayliffe, Andrew: 1 article (01/2022)
4.	Budd, David C: 1 article (01/2022)
5.	Cahn, Anthony: 1 article (01/2022)
6.	Escribano-Subias, Pilar: 1 article (01/2022)
7.	Grünig, Ekkehard: 1 article (01/2022)
8.	Halank, Michael: 1 article (01/2022)
9.	Hall, David A: 1 article (01/2022)
10.	Hanrott, Kate: 1 article (01/2022)

Related Diseases

1.	Pulmonary Arterial Hypertension 01/01/2022 - "An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension."
2.	Vascular Remodeling 01/01/2022 - "While there does not appear to be a consistent acute vasodilatory response to single doses of GSK2586881 in participants with PAH, the potential benefits in terms of chronic vascular remodeling remain to be determined."
3.	Acute Lung Injury 01/01/2017 - "We postulated that repleting ACE2 using GSK2586881, a recombinant form of human angiotensin-converting enzyme 2 (rhACE2), could attenuate acute lung injury. "
4.	Inflammation (Inflammations) 01/01/2018 - "GSK2586881 infusion was associated with reduced plasma markers of inflammation within 2-4 h and increased SOD2 plasma protein at 2 weeks.PAH is characterised by reduced ACE2 activity. "
5.	COVID-19 01/01/2022 - "The recombinant soluble human angiotensin-converting enzyme 2 (rshACE2) is a promising therapy against SARS-CoV-2 infection, but it has some drawbacks that reduce the success of its clinical applications. "

Related Drugs and Biologics

1.	Blood Proteins (Serum Proteins)
2.	Angiotensin-Converting Enzyme 2

Related Therapies and Procedures

1.	Therapeutics